David Bailey's Nakamoto Holdings Going Public Via Merger With KindlyMD; Shares Soar 650%
KindlyMD Inc. (KDLY), an integrated healthcare services provider, has agreed to merge with Nakamoto Holdings, a bitcoin-native holding firm founded by David Bailey, to form a publicly traded BTC treasury vehicle, the company said in a press release Monday.
The combined entity has secured a total of $710 million in financing, $510 million via PIPE, priced at $1.12 per share and consisting of common stock and warrants in KindlyMD, and $200 million in convertible notes, making it the largest capital raise to launch a bitcoin treasury to date.
Nakamoto's/Bailey's strategy centers on accumulating bitcoin and growing per-share BTC holdings through equity, debt, and structured offerings, the release said.
Bitcoin treasury vehicles are becoming increasingly popular as crypto enters the financial mainstream. Strive Asset Management said last week that it was merging with NASDAQ-listed Asset Entities (ASST) to become a publicly traded bitcoin treasury company.
The Nakamoto PIPE attracted over 200 global investors, including VanEck, ParaFi, Arrington Capital, and crypto figures like Adam Back and Balaji Srinivasan, the company said.
KindlyMD will continue its healthcare operations under CEO Tim Pickett, while bitcoin treasury functions shift under Nakamoto's leadership.
The merger is subject to shareholder approval and regulatory clearance, with a new name and ticker to follow.
KDLY shares are soaring in premarket action, ahead 650% to $29 versus Friday's close of $3.90.Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
How To Earn $500 A Month From Campbell's Stock Ahead Of Q3 Earnings
Campbell's Company (NASDAQ:CPB) will release its third-quarter earnings results before the opening bell on Monday, June 2. Analysts expect the Camden, New Jersey-based company to report quarterly earnings at 66 cents per share, down from 75 cents per share in the year-ago period. Campbell's projects to report quarterly revenue of $2.43 billion. Compare that to the $2.37 billion it reported last year, according to data from Benzinga Pro. On May 23, Piper Sandler analyst Michael Lavery maintained Campbell's with an Overweight rating and lowered the price target from $45 to $42. With the recent buzz around Campbell's, some investors may be eyeing potential gains from the company's dividends too. As of now, Campbell's offers an annual dividend yield of 4.57%, which is a quarterly dividend amount of 39 cents per share ($1.56 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $131,418 or around 3,846 shares. For a more modest $100 per month or $1,200 per year, you would need $26,277 or around 769 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.56 in this case). So, $6,000 / $1.56 = 3,846 ($500 per month), and $1,200 / $1.56 = 769 shares ($100 per month). View more earnings on CPB Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. CPB Price Action: Shares of Campbell's gained 1.1% to close at $34.17 on More: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? THE CAMPBELL'S (CPB): Free Stock Analysis Report This article How To Earn $500 A Month From Campbell's Stock Ahead Of Q3 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
S&P 500, stocks inch higher after appeals court unpauses tariffs
US stocks (^DJI, ^IXIC, ^GSPC) edge higher to close out Thursday's session in the green, all while coming off of Nvidia's (NVDA) first quarter earnings and a US appeals court temporarily reversing a trade court's pause on President Trump's tariffs. Market Domination Overtime anchor Julie Hyman and Yahoo Finance markets and data editor Jared Blikre recap the latest market and sector moves after the day's closing bell. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. The Dow recovering a little bit by the end of the day, up 120 points or so, about a fifth of 1%. Remember the trajectory of the day, right? And it's probably shown more clearly in the S&P 500, which at one point was up quite a bit, then dipped into the negative, then finishing higher by about four tenths of 1%. So off the lows of the session. This following the various trade headlines. First, a court blocking a wide swath of President Trump's tariffs. Some still in effect, including sectoral tariffs. Then an appeals court coming in and blocking the block, at least for now. In other words, the tariffs still remain in effect while that case goes to appeal. So still, um, you know, the tariffs perhaps weighing on the market, or at least the base case of the tariffs weighing on the market. The NASDAQ finishing higher as well, by about four tenths of 1%, but it too finishing well off the highs of the session. Jared's got a closer look at the action. Thank you, Julie. Great recap. Nvidia is in the rearview, so that major catalyst off the table right now. And tariffs, they didn't really do too much damage to the market. So green close despite well off the highs there. And I'll just show you the VIX. I'm gonna center on the VIX volatility index with Josh in about 30 minutes here, but you can see it was down today, holding below 20. Uh we can see that in some other markets. And I'll just show you quickly here the 30 year. The 30 year yield down five basis points to 4.92%. So edging away from that 5% line that was causing some hiccups last week. And let's check out the sector action. Only communication services in the red there, that's an alphabet and meta story, but we'll dig into that in a second. Everything else in the green, but as you will notice, real estate here at the top, that's defensive, as is utilities, as is healthcare. So, a little bit of a defensive setup to the bullish action today. Tech had been leading in the early market, and that was thanks to Nvidia. You can see that print right back there, up 3 and 1/4%, but tech lost a lot of momentum over the day. Uh I did mention that communication services was down, Alphabet down three tenths of a percent, that's part of the deal. Apple also, which is tech, that was down about a quarter of a percent. But for the most part, a little bit more green than red. Broadcom also up 1.06%, and if I put a one-year chart on there, you can see it is had, has this nice rounded base and it looks like it wants to break out, might need a little bit more time to form a handle there. We'll have to see what happens, but Broadcom testing its all-time highs right now. Uh, I'm gonna finish here on some of our leaders, and guess what? Biotech was the winner today. So I got two biotech ETFs up at the top, up about 2%, and after that we got Korea, China did well today, regional banks, home builders, which have been kind of downtrodden for some time now, solar energy, and the magnificent seven. On the bottom, what did not work today? Bitcoin down about 1%, also IPOs and software, and small tech. Arc Innovation fund was down two thirds of 1%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the first patient in its Phase 1 clinical trial of CER-1236. The patient was dosed at the lead trial site in a study focused on patients with acute myeloid leukemia (AML). Now more than seven days post-infusion, monitoring continues for key safety, tolerability, and efficacy endpoints. The study will be featured in a poster being presented at the 2025 Annual Meeting of the American Society of Clinical Oncology being held in Chicago May 30-June 3, 2025. Abhishek Maiti, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center, is the lead investigator of the trial. He worked with Cero team on publishing the novel preclinical data in Clinical Cancer Research. The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study has begun with dose escalation to determine the highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK). Robert Sikorski, M.D. Ph.D., CERo Therapeutics' Chief Medical Officer remarked, 'The completion of first-in-human dosing represents a clinical development milestone for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L. Protocol-specified evaluations of safety, pharmacodynamic, pharmacokinetic, and efficacy endpoints are in progress. We look forward to communicating results as data matures.' A peer-reviewed manuscript with robust preclinical data was published earlier in Clinical Cancer Research. The Company is presenting a poster that outlines the Phase 1/1b study at the American Society of Clinical Oncology 2025 Annual Meeting in Chicago May 30-June 3, 2025 at Chicago's McCormick Place Convention Center. The abstract for the poster, titled, 'First in human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-L in acute myeloid leukemia (CertainT-1)' can be found here. The poster session, at which Dr. Sikorski will be present, is being held June 1st, and is titled, 'Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes and Allotransplant.' CERo CEO Chris Ehrlich concluded, 'We are grateful for the participation of our first patient and to the many people who have worked tirelessly to reach this milestone, including our CERO team, our consultants and study sites. We look forward to discussing additional outcomes, which we continue to believe will validate the scientific work performed to date with CER-1236.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@ Investors:CORE IR investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
